Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Dahlbom

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 12, 2026
Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMAJohn Nikitas, Adrien Holzgreve, Jesus Juarez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2025
Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of <sup>177</sup>Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study ProtocolAdrien Holzgreve, Astrid Delker, Zachary Ells, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2020
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate CancerAndreea D Stuparu, Joseph R Capri, Catherine A L Meyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohortJeremie Calais, Andrei Gafita, Matthias Eiber, et al.
The Lancet. Oncology|August 4, 2019
<sup>18</sup>F-fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trialJeremie Calais, Francesco Ceci, Matthias Eiber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U Kishan, Luca F Valle, Holly Wilhalme, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 12, 2026
Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMAJohn Nikitas, Adrien Holzgreve, Jesus Juarez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2025
Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of <sup>177</sup>Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study ProtocolAdrien Holzgreve, Astrid Delker, Zachary Ells, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2020
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate CancerAndreea D Stuparu, Joseph R Capri, Catherine A L Meyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohortJeremie Calais, Andrei Gafita, Matthias Eiber, et al.
The Lancet. Oncology|August 4, 2019
<sup>18</sup>F-fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trialJeremie Calais, Francesco Ceci, Matthias Eiber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U Kishan, Luca F Valle, Holly Wilhalme, et al.
Pageof 8